The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk
The DOI matches its Crossref record; 281 of the 286 references it cites were found in a registry or an index.
Abstract
Controlled clinical studies and clinical experience over many years have proven that virtually all patients benefit from lipid-lowering therapy with statins, even those with normal LDL cholesterol levels. Several recent large outcome trials have further demonstrated the clinical benefits and safety of statins in patients with a wide-range of high risks for cardiovascular disease. Those patients at highest absolute cardiovascular risk generally have the most to gain from statin therapy. A variety of statins are available to lower plasma lipids to guideline levels, but all differ in their pharmacokinetic properties, drug interaction profiles, and risk of myotoxicity. This has been highlighted by the withdrawal of cerivastatin from the market as a result of serious safety concerns. This review examines the safety and effectiveness of statins in special populations at high risk of cardiovascular disease-patients with coronary heart disease, dyslipidaemia, diabetes, hypertension, nephrotic disease, HIV, organ transplant patients and the elderly-with a focus on clinically relevant differences in the properties of individual statins that may influence the risk of drug interactions and side effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several factors including female sex, ethnicity, multisystem disease, and small body frame predispose to SAMS (see Box 1), with the presence of an increasing number of factors associated with greater risk.9,30,32–34”
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Research works printed but not linked: 10
- Farmer JA,Torre-Amione G. Comparative tolerability of the HMG-CoAreductase inhibitors. Drug Saf 2000; 108: 351-352.
- Shek A,Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917. · doi:10.1345/aph.10315 · Paper page
- Kanathur N,Mathai MG,Byrd RP Jr, et al. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-341.
- Lee AJ,Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31. · doi:10.1345/aph.10177 · Paper page
- Thompson GR. Poor responders to statins:Apotential target for stanol esters. Eur Heart J Suppl 1991; 1(Suppl S): S114-S117.
- Gruer PJ,Vega JM,Mercuri MF,Dobrinska MR,Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811-815. · DOI
- Peces R,Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89: 117-118. · DOI
- Regazzi MB,Iacona I,Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporinAin transplant recipients. Transplant Proc 1993; 25: 2732-2734.
- Rozenbaum W,Molina JM,Delfraissy JF, et al. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/abacavir (French substudy, CNA30017). 7th Conference on Retroviruses and Opportunistic Infections; Jan. 3-Feb. 2, 2000; San Francisco, California. Abstract 47.
- Fichtenbaum C,Gerber J,Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. Jan. 30-Feb. 2, 2000; San Francisco, California.
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationSafety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Self-citationClinical Perspectives of Statin-Induced Rhabdomyolysis
Antons, K. A., Williams, C. D., Baker, S. K., & Phillips, P. S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.007 · Cited by 238
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.008 · Cited by 160
The nephrotoxic effects of HAART
Izzedine, H., Harris, M., & Perazella, M. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.142 · Cited by 156
Metadata
- Authors
- Corsini, A.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Corsini, Alberto
- ORCID
- Corsini, Alberto
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2003-05
- Volume
- 17
- Issue
- 3
- Pages
- 265-285
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W2191544621
- Cited by
- 82
- References
- 286
- Citations by year
- 2025: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 2 · 2013: 5 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- statins, drug safety, high cardiovascular risk, lipid-lowering therapy, drug interactions, myotoxicity, coronary artery disease, dyslipidemia, diabetes mellitus, hypertension, nephrotic syndrome, HIV, transplant recipients, elderly patients, statin pharmacokinetics
- MeSH terms
- Aged, Aged, 80 and over, Cardiovascular Diseases, Clinical Trials as Topic, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Hypertension, Kidney Failure, Chronic, Rhabdomyolysis, Transplantation, HIV-1, HIV Infections, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk. https://app.cochat.ai/papers/10.1023/a:1026132412074
- The paper
- Corsini, A. (2003). The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk. Cardiovascular Drugs and Therapy. https://doi.org/10.1023/a%3A1026132412074
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.